Company Overview and News

0
ComCom concerned about Christchurch Airport planned profits

2018-07-18 nzherald.co.nz
The Commerce Commission says Christchurch International Airport may be planning to make excessive profits from security, freight storage, and some terminal lounges, though it's "broadly satisfied" with its planned earnings from most of its assets.
AIA AIA ACKDF AUKNY

0
Is duty free shopping a rip-off? Price comparison reveals it's more expensive to shop at airports

2018-07-09 nzherald.co.nz
Duty-free has long been lauded as a haven of deals, but new research reveals the reality doesn't live up to the hype.
AIA AIA ACKDF AUKNY

0
Listed Airport News For The Month Of June 2018

2018-07-05 seekingalpha
Back in May, we published an article introducing a number of publicly-traded airports around the world. Airports deserve attention as an investment as they are wide-moat businesses backed by a secular trend of growing air traffic.
FPRUY AIA ACKDF AUKNY FPRUF VCISY 0694 5014 SYDDF ANNSF AIA VCISF MYPRY SYD HMCTF

0
NZ shares up; Auckland Airport leads gains

2018-07-05 nzherald.co.nz
New Zealand shares rose in light trading, led higher by Auckland International Airport and Westpac Banking Corp, with Heartland Bank and Fletcher Building softening.
AIA FBU WBC FCREY EBOSY WEBNF WBK ACKDF FRCEF EBO AUKNY EBOSF AIA WBC FBU SKLUY SKL EBO

0
Air New Zealand slams 'excessive pricing' by NZ airports, says law changes could cut plane ticket costs

2018-07-05 nzherald.co.nz
Air New Zealand has slammed the "ravages of airport pricing behaviour" in New Zealand in support of changes to the Commerce Act it says would help curb airport owners' charging and cut air travel costs for passengers.
AIA AIA ANZLY AIR ANZFF ANZFY ACKDF AUKNY AIZ

0
NZ shares mixed in light trading, Sky TV and Stride rise while A2, Westpac drop

2018-07-04 nzherald.co.nz
New Zealand shares were mixed in light trading, with Sky Network Television and Stride Property leading gains while A2 Milk Co and Westpac Banking Corp fell.
AIA WBC WEBNF WBK ACKDF AUKNY SKT SYKWF AIA WBC VTHPF SKKTY GTK SML

26
NZ shares taper off in strong June quarter

2018-06-29 nzherald.co.nz
New Zealand shares ran out of puff in the final day of the June quarter, which has been the strongest quarterly performance in more than two years. Summerset Group Holdings and Ebos Group declined and Westpac Banking Corp gained.
SGM FCREY NZTCF SMSMY ACKDF AUKNY FTRRF KMD SMUPF AOTUF SNZ KMD SML KTHDY AIA FBU WBC SCY SPKKY NZTCY EBOSY SPK WEBNF WBK FRCEF EBO EBOSF AIA WBC FBU EBO

17
Shares gain as market cheers Fletcher Building plans

2018-06-21 nzherald.co.nz
New Zealand shares rallied, pushing the S&P/NZX 50 Index to a record after Fletcher Building detailed its five-year strategy and affirmed guidance. Sky Network Television, A2 Milk, Auckland International Airport and Fisher & Paykel Healthcare rose.
AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY SKT SYKWF AIA PPSHY FBU RYHTY SKKTY SML

10
MARKET WRAP: NZ shares slip after strong run

2018-06-18 nbr.co.nz
The New Zealand market was flat today ahead of several key data points later in the week.
AIA FBU FCREY ZNRGF ACKDF FRCEF ZEL AUKNY ZNZ AIA PPSHY FBU PFGTF

2
First Kiwi bank deal with Alipay smoothes way for Chinese payments

2018-06-11 nzherald.co.nz
It will be easier for Kiwi businesses to take payments via Chinese mobile payment giant Alipay under a deal signed with the Bank of New Zealand.
AIA AIA ACKDF AUKNY

2
Trading mixed in subdued stockmarket

2018-06-11 nzherald.co.nz
New Zealand shares were mixed in subdued trading with the Australian stock exchange closed for their Queen's Birthday public holiday, with local gains led by A2 Milk Co.
AIA AIA ACKDF AUKNY

7
MARKET WRAP: NZ shares continue on record run

2018-06-11 nbr.co.nz
Harbour Asset Management analyst Shane Solly says all eyes will be on Trump’s meeting with Kim Jong Un tomorrow.
AIA RHCGF AIA RYHTY RYM ACKDF AUKNY PFGTF

15
Shares up 1% to new record, A2 and Fletcher gain

2018-06-07 nzherald.co.nz
New Zealand shares surged to a fresh record, led by A2 Milk Co and Fletcher Building amid international demand for Kiwi companies.
KTHDY AIA FBU RHCGF FCREY RYM ACKDF FRCEF AUKNY KWIPF KMD AIA FBU RYHTY KMD

2
Airlines accuse Auckland Airport of making $3.6 billion in excess returns

2018-05-30 nzherald.co.nz
An airline lobby group says Auckland Airport has banked excess profits of $3.6 billion over the past two decades.
AIA AIA ACKDF AUKNY

8
Shares rise led by Auckland Airport and A2 Milk

2018-05-30 nzherald.co.nz
New Zealand shares rose, led by Auckland International Airport, Spark and Fisher & Paykel Healthcare and as buyers returned to A2 Milk. Gentrack Group fell as earnings growth disappointed some bullish investors.
AIA WBC AIA WBC GTK WEBNF GXH WBK ACKDF AUKNY PRCXF

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

CUSIP: ANBKX3XG0